Monopar Therapeutics Inc
monopartx.comMonopar Therapeutics Inc (NASDAQ: MNPR) is a clinical-stage biopharmaceutical company developing drug candidates for rare diseases and cancer. It generates no product revenue, funding operations entirely through equity financing. As of FY2025, the company reported a net loss of $13.7 million on zero revenue, with research and development expenses of $9.9 million and general and administrative expenses of $6.8 million. Cash provided by financing activities totaled $91.6 million in FY2025, sustaining a pipeline that includes ALXN1840, an investigational treatment for Wilson disease, and the MNPR-101 radiopharmaceutical platform targeting uPAR-expressing cancers via zirconium-89 (imaging), lutetium-177 (therapeutic), and actinium-225 (therapeutic) conjugates. All manufacturing is outsourced to third-party contract manufacturers. CEO is Chandler D. Robinson; Executive Chairman is Christopher M. Starr. The 10-K was filed March 27, 2026, for fiscal year ended December 31, 2025.
Products & Services
ALXN1840: investigational oral drug candidate for Wilson disease (rare copper metabolism disorder). MNPR-101-Zr: uPAR-targeted imaging agent in clinical trial for advanced cancer patients. MNPR-101-Lu: uPAR-targeted lutetium-177 therapeutic radiopharmaceutical in clinical development. MNPR-101-Ac: uPAR-targeted actinium-225 therapeutic radiopharmaceutical in development.
Revenue Model
No product revenue as of FY2025. Operations are financed through equity capital raises. The company expects future revenue from product sales, and potentially licensing, milestone, or royalty payments, if drug candidates receive regulatory approval.
Customers & Markets
Target patient populations are individuals with Wilson disease and patients with advanced cancers expressing uPAR. No commercial customers as of FY2025. End markets are rare disease and oncology, specifically radiopharmaceutical oncology.
Geographic Exposure
Incorporated and headquartered in the United States. Regulatory filings reference U.S. FDA, EU EMA, Canadian Health Canada, and Japanese Ministry of Health, Labor and Welfare, indicating multi-jurisdiction development intent. Foreign currency exposure acknowledged in FY2025 filing.
Financial Snapshot
Loading...
